SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants selection to support The Clearing Houses on-chain money initiative is the main catalyst, with traders viewing the bank-infrastructure project as evidence of growing institutional adoption. The rally has also sparked debate over whether the deal will create meaningful demand for the QNT token, alongside profit-taking and concern that implementation and token benefits remain uncertain.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop 10 kV silicon-carbide power devices and validate a domestic manufacturing process is drawing attention as a technology-validation milestone. Many traders see potential in defense, grid and AI-power applications, while others caution that it is a prototype program with undisclosed financial termsnot evidence of significant near-term revenueand debate the stocks volatile reaction.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment and clinical collaboration with Summit are driving attention, with traders welcoming the added funding and validation for ivonescimab while debating whether the deal is being overhyped as a takeover signal. The agreement is not a buyout, and investors remain focused on the drugs clinical and FDA-review risks.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK results for two investigational wet AMD drugs, which met their primary endpoints against Eylea, drove a sharp rally. Traders are celebrating the potential progress toward an FDA filing, while others question the drugs competitive edge and warn that the valuation, future financing needs, and possible dilution could weigh on the shares.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rebound and rising volume have fueled momentum chatter, with traders pointing to altcoin rotation and Avalanches tokenization/RWA narrativeincluding reported institutional securities-platform interest. Others question whether the move reflects durable adoption or a speculative pump, and warn of a pullback.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is under pressure after positive late-stage results from wet-AMD rival Kodiak Sciences renewed concerns about competition for AXPAXLI. Traders debate whether Kodiaks results meaningfully challenge AXPAXLI, with some arguing its dosing and trial design make the comparison less concerning.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibres Q2 results sparked debate after strong revenue growth and earnings beats were followed by a share-price selloff, as margin compression and lower profit raised concerns about heavy spending on shipping, logistics, and credit expansion. Bulls view the pressure as investment in the companys Latin American commerce and fintech ecosystem, while skeptics question when profitability will recover and whether credit risks are rising.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys Texas eIPP flights and completed autonomous cross-country flight are drawing attention, with traders debating whether these demonstrations and progress toward final FAA certification bring commercial operations closer. Bulls view them as meaningful milestones, while skeptics focus on the long certification path, cash burn, dilution and continued share-price weakness.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman shares recent weakness and underperformance are drawing attention, with traders pointing to pressure across bank stocks, higher-rate and yield-curve concerns, and softer near-term capital-markets expectations. Bulls counter that the selloff leaves a profitable franchise looking undervalued and expect earnings strength to help, while others remain wary ahead of results.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs prolonged selloff and fresh lows are being tied to disappointing Q2 results and weaker-than-expected Q3 guidance, with traders focused on soft vehicle margins, ongoing losses, and intense China EV price competition. Bullish traders counter that the robotics units outside funding and growth potential could add value, but the near-term debate centers on whether that story can outweigh profitability and delivery concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Slickaj115

Andrew R